Qilu Pharm Hainan Company Profile
✉ Email this page to a colleague
What is the competitive landscape for QILU PHARM HAINAN
QILU PHARM HAINAN has nineteen approved drugs.
Drugs and US Patents for Qilu Pharm Hainan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qilu Pharm Hainan | IMATINIB MESYLATE | imatinib mesylate | TABLET;ORAL | 212135-002 | Jun 21, 2022 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Qilu Pharm Hainan | DOXORUBICIN HYDROCHLORIDE | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 219881-002 | Feb 3, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Qilu Pharm Hainan | IRINOTECAN HYDROCHLORIDE | irinotecan hydrochloride | INJECTABLE;INJECTION | 203380-001 | May 3, 2016 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Qilu Pharm Hainan | PALONOSETRON HYDROCHLORIDE | palonosetron hydrochloride | INJECTABLE;INTRAVENOUS | 205648-002 | Sep 19, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Qilu Pharm Hainan | PEMETREXED DISODIUM | pemetrexed disodium | POWDER;INTRAVENOUS | 204890-002 | May 25, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Qilu Pharm Hainan | POSACONAZOLE | posaconazole | TABLET, DELAYED RELEASE;ORAL | 217720-001 | Apr 23, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

